Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Host response-based screening to identify undiagnosed cases of COVID-19 and expand testing capacity

Nagarjuna R. Cheemarla, Anderson F. Brito, Joseph R. Fauver, Tara Alpert, Chantal B.F. Vogels, Saad B. Omer, Albert I. Ko, Nathan D. Grubaugh, Marie L. Landry, View ORCID ProfileEllen F. Foxman
doi: https://doi.org/10.1101/2020.06.04.20109306
Nagarjuna R. Cheemarla
1Department of Laboratory Medicine, Yale School of Medicine, New Haven CT, 06520
2Department of Immunobiology, Yale School of Medicine, New Haven CT, 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anderson F. Brito
3Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph R. Fauver
3Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tara Alpert
5Department of Molecular Biophysics and Biochemistry, Yale School of Medicine, New Haven CT, 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chantal B.F. Vogels
3Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saad B. Omer
3Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, 06520
4Yale Institute of Global Health, Yale School of Public Health, New Haven, CT, 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert I. Ko
3Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan D. Grubaugh
3Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie L. Landry
1Department of Laboratory Medicine, Yale School of Medicine, New Haven CT, 06520
6Department of Internal Medicine, Yale School of Medicine, New Haven CT, 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ellen F. Foxman
1Department of Laboratory Medicine, Yale School of Medicine, New Haven CT, 06520
2Department of Immunobiology, Yale School of Medicine, New Haven CT, 06520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ellen F. Foxman
  • For correspondence: ellen.foxman@yale.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The COVID-19 pandemic has created unprecedented challenges in diagnostic testing. At the beginning of the epidemic, a confluence of factors resulted in delayed deployment of PCR-based diagnostic tests, resulting in lack of testing of individuals with symptoms of the disease. Although these tests are now more widely available, it is estimated that a three- to ten-fold increase in testing capacity will be required to ensure adequate surveillance as communities reopen1. In response to these challenges, we evaluated potential roles of host response-based screening in the diagnosis of COVID-19. Previous work from our group showed that the nasopharyngeal (NP) level of CXCL10, a protein produced as part of the host response to viral infection, is a sensitive predictor of respiratory virus infection across a wide spectrum of viruses2. Here, we show that NP CXCL10 is elevated during SARS-CoV-2 infection and use a CXCL10-based screening strategy to identify four undiagnosed cases of COVID-19 in Connecticut in early March. In a second set of samples tested at the Yale New Haven Hospital, we show that NP CXCL10 had excellent performance as a rule-out test (NPV 0.99, 95% C.I. 0.985-0.997). Our results demonstrate how biomarker-based screening could be used to leverage existing PCR testing capacity to rapidly enable widespread testing for COVID-19.

One Sentence Summary We describe a host-response based screening strategy to identify undiagnosed cases of COVID-19 and to expand capacity for PCR-based testing.

Competing Interest Statement

Competing interest statement. E.F. and M.L. have filed the following patent application related to the topic of this work: E. F. Foxman and M. Landry, inventors. 2017 Oct 11., Methods for Detecting Respiratory Virus Infection, WO patent application PCT/US17/056076.

Funding Statement

Funding was provided by the N.I.H. (K08 AI119139 to E.F.F.) the Hartwell Foundation (to E.F.F.), the Yale Department of Laboratory Medicine (to E.F.F.), the Yale School of Public Health (to N.D.G), and the Huffman Family Donor Advised Fund (to N.D.G). C.B.F.V. is supported by NWO Rubicon 019.181EN.004.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Project was carried out according to IRB-approved protocol #2000027656 with oversight from the Yale Human Investigations Committee.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data is provided in the manuscript. Additional details are available upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 05, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Host response-based screening to identify undiagnosed cases of COVID-19 and expand testing capacity
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Host response-based screening to identify undiagnosed cases of COVID-19 and expand testing capacity
Nagarjuna R. Cheemarla, Anderson F. Brito, Joseph R. Fauver, Tara Alpert, Chantal B.F. Vogels, Saad B. Omer, Albert I. Ko, Nathan D. Grubaugh, Marie L. Landry, Ellen F. Foxman
medRxiv 2020.06.04.20109306; doi: https://doi.org/10.1101/2020.06.04.20109306
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Host response-based screening to identify undiagnosed cases of COVID-19 and expand testing capacity
Nagarjuna R. Cheemarla, Anderson F. Brito, Joseph R. Fauver, Tara Alpert, Chantal B.F. Vogels, Saad B. Omer, Albert I. Ko, Nathan D. Grubaugh, Marie L. Landry, Ellen F. Foxman
medRxiv 2020.06.04.20109306; doi: https://doi.org/10.1101/2020.06.04.20109306

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (577)
  • Anesthesia (139)
  • Cardiovascular Medicine (1942)
  • Dentistry and Oral Medicine (252)
  • Dermatology (183)
  • Emergency Medicine (331)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (697)
  • Epidemiology (11086)
  • Forensic Medicine (8)
  • Gastroenterology (619)
  • Genetic and Genomic Medicine (3156)
  • Geriatric Medicine (307)
  • Health Economics (560)
  • Health Informatics (2037)
  • Health Policy (861)
  • Health Systems and Quality Improvement (781)
  • Hematology (309)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12702)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2977)
  • Nursing (162)
  • Nutrition (461)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1548)
  • Ophthalmology (474)
  • Orthopedics (185)
  • Otolaryngology (265)
  • Pain Medicine (201)
  • Palliative Medicine (57)
  • Pathology (402)
  • Pediatrics (909)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (354)
  • Psychiatry and Clinical Psychology (2774)
  • Public and Global Health (5583)
  • Radiology and Imaging (1090)
  • Rehabilitation Medicine and Physical Therapy (630)
  • Respiratory Medicine (755)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (287)
  • Surgery (342)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (131)